Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: DR. BOND who wrote (797)	11/18/1997 6:47:00 PM
From: TradeOfTheDay	Read Replies (1) \| Respond to of 7041

But why were you surprised? I think there have been several people on this thread who said the field was so vast, that there was room for MANY different types of therapy, to deal with many different causes and degrees of ED. And anyone would be foolish not to realize that a marketing machine like PFE, is going to create a waterfall effect for all comapanies involved. Like anything else - what works will survive. Wish you fellows would relax over there.

To: DR. BOND who wrote (797)	11/18/1997 6:49:00 PM
From: Scott Kelly	Respond to of 7041

Harvard Scientific's Board of Directors Appoints Thomas E. Waite asIts New President, CEO and Chairman of the BoardRENO, Nevada, Nov. 18 /PRNewswire/ -- Harvard Scientific Corp. (OTCBulletin Board: HVSF), a Nevada corporation, announced today thatits Board of Directors has appointed Thomas E. Waite as presidentand CEO of the company. Mr. Waite will also serve as Chairman ofthe Board of Directors. Mr. Waite brings to the company years ofdirect experience in the company's business operations andpreviously served the company as a consultant. Prior to his appointment, Waite was the President of Thomas E.Waite & Associates in Lake Mary, FL, a consulting firm thatspecialized in the areas of investment banking, corporate finance,merger/acquisitions and public relations for publicly tradedcompanies. As part of Waite's employment agreement, he has agreedto divest his current interests in Thomas E, Waite & Associates andto concentrate his effort full time to the affairs of the company. In an interview, Waite stated, "My first concern and priority isto strengthen the company's balance sheet while at the same timedesigning a concise road map which the company can follow throughthe Phase II/III clinical trials and the marketing of its products. I believe the issuance of the company's patent for its ProstaglandinE-1 (PGE-1) erectile dysfunction product has greatly enhanced itsability to compete in the U.S. market as well as strengthening itsposition worldwide." Harvard Scientific Corp. is a biopharmaceutical company thatdevelops, markets and distributes products relating to liposomaldelivery of PGE-1 for the treatment of male erectile dysfunction,impotency and sexual enhancement. The company's patent pendingprocess allows the PGE-1 to be administered as a liquid via apainless delivery system, PGE-1 is a naturally occurring vasodilatororiginally approved by the U.S. FDA for intravenous infusion inneonates. PGE-1 was first approved by the FDA for Upjohn'streatment for male erectile dysfunction via needle injection in 1995and approved in November, 1996, for Vivus, Inc.'s MUSE deliverysystems. The company believes its product represents a tremendoustreatment advantage over other delivery systems currently beingutilized in the industry. From time to time the company may issue forward-lookingstatements which involve risks and uncertainties. This news releasemay contain forward- looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended. Actualresults could differ and any forward-looking statements should beconsidered accordingly,SOURCE Harvard Scientific Corp. 11/18/97/CONTACT: Irwin Miller of I.W. Miller & Co., Inc., 800-691-9991/ /Web site: harvardscientific.com (HVSF)